Position in GILD
as of Jun 30, 2026
· filed Jul 13, 2026
Position Value
$436,125
-$34,109 QoQ
Shares Held
3,452
+2.3% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.25%
of 13F equity value
Holder Rank
#1,446
of 2,266 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GILD Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Southland Equity Partners LLC holds $15,588,502 across 9 Drug Manufacturers - General names. GILD ranks #6 (2.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
28,242 | $7,106,816 | |
| 2 | JNJ |
Johnson & Johnson
|
20,549 | $5,218,829 | |
| 3 | LLY |
ELI LILLY & Co
|
693 | $831,205 | |
| 4 | NVS |
Novartis AG
|
3,807 | $596,633 | |
| 5 | AMGN |
Amgen Inc
|
1,418 | $513,486 | |
| 6 | GILD |
Gilead Sciences, Inc.
This page
|
3,452 | $436,125 | |
| 7 | NVO |
Novo Nordisk A S
|
7,811 | $374,459 | |
| 8 | MRK |
Merck & Co., Inc.
|
2,154 | $276,789 |
All Filings in GILD
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $436,125 | 3,452 | Shares | Sole | 2026-07-13 | |
| 2026-03-31 | $470,234 | 3,374 | Shares | Sole | 2026-04-14 | |
| 2025-12-31 | $407,128 | 3,317 | Shares | Sole | 2026-01-14 | |
| 2025-09-30 | $367,854 | 3,314 | Shares | Sole | 2025-10-15 | |
| 2025-06-30 | $364,207 | 3,285 | Shares | Sole | 2025-07-14 | |
| 2025-03-31 | $357,775 | 3,193 | Shares | Sole | 2025-04-16 | |
| 2024-12-31 | $288,933 | 3,128 | Shares | Sole | 2025-01-21 | |
| 2024-09-30 | $253,029 | 3,018 | Shares | Sole | 2024-10-15 | |
| 2024-06-30 | $204,183 | 2,976 | Shares | Sole | 2024-07-12 | |
| No filing history on record for this holder in this stock. | ||||||